Publications Here you can find scientific publications BiKeR project in reverse chronological order: Long-term safety of etanercept and adalimumab Compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Klotsche J, Niewerth M, Haas JP, Huppertz HI, zinc O, Horneff G, Minden K. Ann Rheum Dis. 2015 April 29 pii: annrheumdis-2014-206747. doi: 10. 1136 / annrheumdis-annrheumdis-2014-206747 Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Nimmrich S, Horneff G. Rheumatol Int. 2015 Mar; 35 (3): 465-70. doi: 10.
1007 / s00296-014-3197-6. Epub 2015 January 13 [Current news from the BIKER register]. Horneff G, K Minden, Földvári I, Onken N, wind sound D, Hospach A, G Ganser, Klotsche J, Becker I; BIKER Register Study Group. Z Rheumatol. 2014 Dec; 73 (10): 897-906. doi: 10. 1007 / s00393-014-1397-9. German. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years. Wind noise D, Müller T, Becker I, Horneff G. Rheumatol Int. 2015 April; 35 (4): 613-8.
doi: 10. 1007 / s00296-014-3125-9. Epub 2014 Sep 11th Predictors of response to methotrexate in juvenile idiopathic arthritis. Albarouni M, Becker I, Horneff G. Pediatr Rheumatol Online J. 2014 Aug 13; 12: 35th doi: 10. 1186 / 1546-0096-12-35. eCollection, 2014. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Wind noise D, Müller T, Becker I, Horneff G. Clin Rheumatol. 2015 Jan; 34 (1): 61-9.
doi: 10. 1007 / s10067-014-2744-6. Epub 2014 Jul 18th Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA registry. Schmeling H, K Minden, Földvári I, Ganser G, T Hospach, Horneff G. Arthritis Rheumatol. 2014 SEP and 66 (9): 2580-9. doi: 10. 1002 / art. 38741. Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score. Horneff G, Becker I. Rheumatology (Oxford).
2014 July; 53 (7): 1229-34. doi: 10. 1093 / rheumatology / ket470. Epub 2014 Mar. 4 Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group. Rheumatology (Oxford). 2014 July; 53 (7): 1245-9. doi: 10. 1093 / rheumatology / ket490. Epub 2014 Mar. 4
Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Klotsche J, K Minden, Thon A, G Ganser, Urban A, Horneff G. Arthritis Care Res (Hoboken). 2014 February; 66 (2): 253-62. doi: 10. 1002 / acr. 22112 Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Small A, Kaul I, I Földvári, Ganser G, Urban A, Horneff G. Arthritis Care Res (Hoboken). 2012 SEP and 64 (9): 1349-56. doi: 10. 1002 / acr.
21697 Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis Treated with etanercept. van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, W Armbrust, Minden K, Prince FH, FT coccus, Nieuwenhuis EE, Horneff G, WulffraatNM. J Rheumatol. 2011 July; 38 (7): 1441-6. Epub 2011 April. 1 Summary National JIA register in the Netherlands, Germany, Finland, Denmark and Italy were searched for JIA patients who were sick also to inflammatory bowel disease (IBD). It was investigated whether treatment with etanercept lead in JIA patients to higher incidence rates of IBD. 13 cases of IBD in JIA patients were found in 1999 by 2008. The IBD coincidence with JIA patients with etanercept treatment was 362 per 100,000 patient years, 43 times higher than in the general pediatric population. Report on malignancies in the German juvenile idiopathic arthritis registry.
Horneff G, Földvári I, Minden K, D Moebius, Hospach T. Rheumatology (Oxford). 2011 Jan; 50 (1): 230-6. Summary Reports of malignancies in children who were exposed to TNF inhibitors, raise questions with regard to increased risk for malignant lymphomas. In German JIA registers found between 2001 and 2009 Classificação de 5 the total 1260 patients who had a malignancy. All 5 patients were exposed to a variety of cytotoxic agents (inter alia MTX, LEF, AZA, CSA) before they were treated with TNF-α blockers. Malignancies have been observed for a period of treatment with etanercept from 3 weeks to> 6 years. While in some of the patients the treatment time with TNF blockers was too short to determine a recognizable reference, the long preliminary treatment could be causative for other patients studied. JIA patients treated with biologics, or cytotoxic agents should be accompanied observed thoroughly malignancies – in the longer term, in adult life. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Papsdorf V, Horneff G. Rheumatology (Oxford).
2011 Jan; 50 (1): 214-21. Erratum in: Rheumatology (Oxford). 2011 April; 50 (4): 814 Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Horneff G. Z Rheumatol. 2010 Aug; 69 (6): 516-26. Review. German. Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA’s report Regarding malignancies in anti-TNF-treated patients from Aug. 4, of 2009. Horneff G, T Hospach, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, K Minden, Trauzeddel R. Z Rheumatol.
2010 Aug; 69 (6): 561-7. German. Safety and efficacy of once weekly etanercept 0. 8 mg / kg in a multicentre trial in 12 week active polyarticular course juvenile idiopathic arthritis. Horneff G, Ebert A, S Fitter, Minden K, Földvári I Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI. Rheumatology (Oxford). 2009 August; 48 (8): 916-9. Epub 2009 May 29th Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Halbig M, Horneff G. Rheumatol Int. 2009 Dec; 30 (2): 229-38 Safety and efficacy of combination of etanercept and methotrexate Compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry.
Horneff G, De Bock F, Földvári I Girschick HJ, Michels H, D Moebius, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group. Ann Rheum Dis. 2009 April; 68 (4): 519-25. Epub 2008 April 15 Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Tzaribachev N, Kuemmerle-Deschner J, M Eichner, Horneff G. Rheumatol Int. 2008 August; 28 (10): 1031-4. Epub 2008 Mar 28 Safety and efficacy of once-weekly application of etanercept in children with juvenile idiopathic arthritis. Kuemmerle-Deschner JB, Horneff G. Rheumatol Int. 2007 Dec; 28 (2): 153-6.
Epub 2007 Jul 20th Etanercept and uveitis in patients with juvenile idiopathic arthritis. Schmeling H, Horneff G. Rheumatology (Oxford). 2005 August; 44 (8): 1008-11. Epub 2005 April 26 The German registry etanercept for treatment of juvenile idiopathic arthritis. Horneff G, H Schmeling, Biedermann T, Földvári I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Sexton RM, Michels H, D Moebius, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group. Ann Rheum Dis. 2004 Dec; 63 (12): 1638-44. Epub 2004 28 Apr Review.